Serum creatine kinase in the diagnosis of acute myocardial infarction. Optimal sampling frequency. 1983

M L Fisher, and N H Carliner, and L C Becker, and R W Peters, and G D Plotnick

To document optimal sampling frequency, we reviewed creatine kinase (CK) myocardial specific isoenzyme (CKMB) results in 314 patients with suspected acute myocardial infarction (MI). In 127 patients with elevated CK/CKMB, peak CK observed using all samples (every four-hour [Q4hr] method) was compared with results that would have been obtained had samples been taken on admission and either twice daily (every 12-hour [Q12hr] method) or once daily (every 24-hour [Q24hr] method). Although average peak CK was statistically different (Q4hr greater than Q12hr greater than Q24hr), major underestimation of peak CK (greater than or equal to 500 units/L) was uncommon (3%) using the Q12hr method, suggesting that Q12hr sampling is a practical, cost-effective approach for patients with suspected acute MI.

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D003402 Creatine Kinase A transferase that catalyzes formation of PHOSPHOCREATINE from ATP + CREATINE. The reaction stores ATP energy as phosphocreatine. Three cytoplasmic ISOENZYMES have been identified in human tissues: the MM type from SKELETAL MUSCLE, the MB type from myocardial tissue and the BB type from nervous tissue as well as a mitochondrial isoenzyme. Macro-creatine kinase refers to creatine kinase complexed with other serum proteins. Creatine Phosphokinase,ADP Phosphocreatine Phosphotransferase,ATP Creatine Phosphotransferase,Macro-Creatine Kinase,Creatine Phosphotransferase, ATP,Kinase, Creatine,Macro Creatine Kinase,Phosphocreatine Phosphotransferase, ADP,Phosphokinase, Creatine,Phosphotransferase, ADP Phosphocreatine,Phosphotransferase, ATP Creatine
D004796 Clinical Enzyme Tests Analyses for a specific enzyme activity, or of the level of a specific enzyme that is used to assess health and disease risk, for early detection of disease or disease prediction, diagnosis, and change in disease status. Enzyme Tests, Clinical,Clinical Enzyme Test,Enzyme Test, Clinical,Test, Clinical Enzyme,Tests, Clinical Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

M L Fisher, and N H Carliner, and L C Becker, and R W Peters, and G D Plotnick
September 1983, JAMA,
M L Fisher, and N H Carliner, and L C Becker, and R W Peters, and G D Plotnick
September 1990, Lancet (London, England),
M L Fisher, and N H Carliner, and L C Becker, and R W Peters, and G D Plotnick
February 1973, British medical journal,
M L Fisher, and N H Carliner, and L C Becker, and R W Peters, and G D Plotnick
May 1980, British heart journal,
M L Fisher, and N H Carliner, and L C Becker, and R W Peters, and G D Plotnick
October 1977, Lancet (London, England),
M L Fisher, and N H Carliner, and L C Becker, and R W Peters, and G D Plotnick
January 1981, Indian heart journal,
M L Fisher, and N H Carliner, and L C Becker, and R W Peters, and G D Plotnick
January 1965, The American journal of cardiology,
M L Fisher, and N H Carliner, and L C Becker, and R W Peters, and G D Plotnick
January 1977, Review of Czechoslovak medicine,
M L Fisher, and N H Carliner, and L C Becker, and R W Peters, and G D Plotnick
January 1978, Acta medica Scandinavica. Supplementum,
M L Fisher, and N H Carliner, and L C Becker, and R W Peters, and G D Plotnick
November 1991, Annals of clinical biochemistry,
Copied contents to your clipboard!